Drugs / SIBP-03
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05203601 | Nov 2020 → Dec 2022 | neoplasm | Shanghai Institute Of Biological Products | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06194656 | Sep 2024 → Jul 2026 overdue | head and neck squamous cell carcinoma | Shanghai Institute Of Biological Products | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sibp-03 | “Part one, 12 subjects were randomly assigned 1:1 to two groups and treated with SIBP-03 dose A or dose B every 3 weeks (Q3W) combined with cetuximab every week (QW).” NCT06194656 ↗ |
| Modality | Monoclonal antibody | “Recombinant anti-HER3 humanized monoclonal antibody injection” NCT05203601 ↗ |
| Route | Intravenous | “Dose A, intravenous infusion (IV), once every three weeks, 21 days as a cycle.” NCT06194656 ↗ |